Summary & Overview
CPT 81436: Genetic Testing Procedure
CPT code 81436 represents a genetic testing procedure commonly performed in laboratory settings to support the diagnosis and management of various hereditary and neoplastic conditions. This code is scheduled for deletion on December 31, 2024, marking a notable shift in the coding landscape for genetic testing services. Nationally, genetic testing is a rapidly evolving field, and changes in CPT codes can impact billing practices, payer coverage, and clinical workflows.
Key payers covered in this analysis include Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides an overview of the clinical context for CPT 81436, including its typical use cases, associated diagnoses, and relevant modifiers. Readers will gain insight into policy updates, coding changes, and payer coverage trends related to genetic testing. The summary also highlights the importance of understanding the implications of code deletions and updates for laboratories, clinicians, and billing professionals.
This article is designed to inform stakeholders about the national significance of CPT 81436, offering benchmarks and policy perspectives that are relevant across the healthcare industry. The content is organized to provide clear, concise information on the code's clinical applications, payer coverage, and upcoming changes, ensuring readers are prepared for the evolving landscape of genetic testing billing.
CPT Code Overview
CPT 81436 is a code used for genetic testing services, typically performed in a laboratory setting (POS 81). This code has been marked for deletion effective December 31, 2024. Genetic testing plays a critical role in identifying hereditary conditions and informing clinical decision-making. Laboratories specializing in medical genetics utilize this code to bill for advanced genetic analyses that support patient diagnosis and management. The deletion of CPT 81436 signals a significant change in coding practices for genetic testing services.
Clinical & Coding Specifications
Clinical Context
A patient presents with a personal or family history suggestive of hereditary cancer syndromes, such as colorectal or endometrial cancer. The ordering physician, typically a specialist in medical genetics, requests comprehensive genetic testing to identify potential pathogenic variants associated with these malignancies. The procedure is performed in a laboratory setting (Place of Service 81), where advanced molecular techniques are used to analyze the patient's DNA. The results inform clinical management, including risk assessment and potential targeted therapies.
Coding Specifications
-
Modifier
26: Used to indicate the professional component of the service, such as interpretation of genetic test results by a qualified provider. -
Modifier
59: Used to denote a distinct procedural service, indicating that the genetic test is separate from other procedures performed on the same day.
| Modifier Code | Description |
|---|---|
26 | Professional Component |
59 | Distinct Procedural Service |
- Associated Provider Taxonomies:
| Taxonomy Code | Specialty Description |
|---|---|
207SG0201X | Medical Genetics, Ph.D. Medical Genetics |
207SC0300X | Medical Genetics, Clinical Genetics (M.D.) |
207SG0202X | Medical Genetics, Clinical Biochemical Genetics |
207SG0203X | Medical Genetics, Clinical Molecular Genetics |
Related Diagnoses
-
C18.0‑C18.8: Malignant neoplasm of colon- Relevant for patients undergoing genetic testing to assess hereditary risk for colon cancer.
-
C19: Malignant neoplasm of rectum- Indicates rectal cancer, which may be associated with hereditary cancer syndromes.
-
C20: Malignant neoplasm of anal canal- Genetic testing may be performed to evaluate risk factors for anal canal malignancies.
-
C21.1: Malignant neoplasm of cloacogenic zone- Used for patients with rare anal cancers, potentially linked to genetic predisposition.
-
C21.2: Malignant neoplasm of overlapping sites of rectum, anus, and anal canal- Indicates complex cases where genetic testing can clarify hereditary risk.
-
C21.8: Malignant neoplasm of other specified sites of rectum, anus, and anal canal- Relevant for broader assessment of hereditary cancer risk.
-
C54.0‑C54.3: Malignant neoplasm of corpus uteri, endometrial neoplasms- Genetic testing is important for patients with endometrial cancer to evaluate for syndromes such as Lynch syndrome.
-
C54.8: Malignant neoplasm of other specified sites of corpus uteri- Used for patients with less common uterine cancers, where genetic evaluation may be indicated.
Related CPT Codes
Data not available in the input.
National Reimbursement Benchmarks
National mean rates for CPT code 81436 show that UnitedHealth Group has the highest average reimbursement at $1,046.22, followed by Cigna at $854.83, BUCA (average commercial) at $657.15, and Blue Cross Blue Shield at $530.18. Medicare rates are not available in the input, so a comparison to Medicare is not possible.
Rate dispersion varies significantly across payers. Cigna has the tightest range, with a difference of $74.00 between the 75th and 25th percentiles, indicating relatively consistent rates. In contrast, UnitedHealth Group exhibits the widest dispersion, with a $1,026.00 difference between the 75th and 25th percentiles, reflecting substantial variability in reimbursement. Blue Cross Blue Shield and BUCA show moderate dispersion, with ranges of $146.50 and $357.00, respectively.
The table and chart below present the full breakdown of national benchmarks for CPT code 81436 by payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.